Why Wegovy (Semaglutide 2.4 mg) Causes Sulfur Burps: The Mechanism Explained

At a glance

• Incidence: Eructation reported in approximately 3-5% of participants on semaglutide 2.4 mg in the STEP trials; sulfur-specific character is underreported in trial data but frequently described in post-marketing surveillance
• Typical timeline: Onset within 1-3 weeks of each dose escalation; often peaks at the 1.0-1.7 mg transition phase
• Mechanism: GLP-1 receptor activation on vagal afferents and gastric smooth muscle delays emptying, extending bacterial fermentation time for sulfur-containing substrates
• First-line management: Reduce sulfur-rich foods (eggs, cruciferous vegetables, alliums), eat smaller meals, consider bismuth subsalicylate for acute episodes
• When to escalate: If accompanied by persistent vomiting, abdominal distension, or inability to tolerate oral medications
• When to discontinue: Rarely necessary for sulfur burps alone; discuss with prescriber if symptoms suggest gastroparesis (solid food intolerance >72 hours)

How GLP-1 Receptor Activation Alters Gastric Motility

Semaglutide binds GLP-1 receptors expressed on vagal afferent neurons in the gastric wall and on myenteric plexus neurons controlling antral contractions. This binding triggers a signaling cascade that suppresses antral motility and relaxes the proximal stomach, collectively slowing the rate at which gastric contents pass through the pylorus into the duodenum. Scintigraphy studies demonstrate that semaglutide 1.0 mg delays gastric half-emptying time by approximately 30-38% compared to placebo, with the 2.4 mg dose producing proportionally greater delays during the initial weeks of treatment.

The pyloric sphincter also receives direct GLP-1 receptor-mediated tonic input. Research using antroduodenal manometry confirms that GLP-1 agonists increase pyloric pressure and reduce the frequency of isolated pyloric pressure waves that normally propel chyme forward. This creates a functional "bottleneck" that keeps food in the stomach substantially longer than the typical 2-4 hour window.

At the 2.4 mg maintenance dose used in Wegovy, this gastric retention can extend solid-food residence times to 6-8 hours in some patients, particularly during dose escalation when receptor sensitivity is highest.

From Delayed Emptying to Hydrogen Sulfide Production

The stomach is not sterile. A population of acid-tolerant bacteria (primarily Streptococcus, Lactobacillus, and Veillonella species) colonizes the gastric mucosa and ingested food bolus. Under normal emptying conditions, these organisms have limited time to metabolize substrates before chyme moves distally. When food sits for extended periods, sulfate-reducing bacteria gain sufficient time to convert sulfur-containing amino acids (cysteine, methionine) and inorganic sulfates into hydrogen sulfide gas.

The biochemistry is straightforward. Cysteine undergoes desulfhydration to produce H₂S, pyruvate, and ammonia. Methionine is demethylated to homocysteine, then cleaved to release H₂S. These reactions occur at rates proportional to substrate concentration and bacterial exposure time, both of which increase when gastric emptying slows.

H₂S has a detection threshold in humans of just 0.5 parts per billion. Even modest increases in gastric H₂S production therefore produce a noticeable sulfurous taste and odor during eructation. The gas accumulates in the gastric fundus, and transient lower esophageal sphincter relaxations (tLESRs) release it upward as a sulfur burp.

Why Certain Foods Make It Worse

Not all meals produce equal H₂S. Foods with high concentrations of sulfur-containing compounds serve as the primary substrates:

• Eggs: Contain 130-180 mg methionine per large egg and significant cysteine content
• Cruciferous vegetables: Broccoli, cauliflower, cabbage, and Brussels sprouts contain glucosinolates that gut bacteria hydrolyze to release sulfur compounds
• Allium vegetables: Garlic and onions contain diallyl sulfides and thiosulfinates
• Red meat: Higher methionine density per gram than poultry or fish
• Beer and wine: Contain sulfites (SO₂) added as preservatives

When these foods remain in a semaglutide-slowed stomach for 6+ hours instead of the normal 2-3 hours, bacterial fermentation time roughly doubles or triples. The relationship between gastric retention time and gas production follows a near-linear dose-response curve in fermentation studies, meaning each additional hour of retention produces proportionally more H₂S.

The Dose-Escalation Pattern

Sulfur burps characteristically peak during the titration phase of Wegovy therapy. The STEP 1 trial documented that gastrointestinal adverse events, including eructation, were most frequent during the 16-week dose-escalation period and declined at maintenance. This pattern has a pharmacological explanation.

During early exposure to each new dose level, GLP-1 receptors on vagal afferents have not yet undergone tachyphylaxis. The full receptor-mediated slowing of gastric emptying occurs. Over 4-8 weeks at a stable dose, partial receptor desensitization occurs through beta-arrestin mediated internalization, moderately restoring emptying rates. Patients often report that sulfur burps improve substantially by weeks 3-4 at each dose plateau, only to recur when the next titration step begins.

The STEP 3 trial combined semaglutide 2.4 mg with intensive behavioral therapy including dietary counseling, and reported lower rates of GI complaints overall, suggesting that dietary modification during titration can meaningfully reduce symptom burden.

Distinguishing Sulfur Burps from Concerning Pathology

Sulfur burps from Wegovy are benign but unpleasant. They should be distinguished from conditions requiring clinical intervention:

Gastroparesis: If sulfur burps are accompanied by early satiety with <50% of a normal meal, vomiting undigested food more than 6 hours after eating, or progressive abdominal distension, consider formal gastric emptying assessment. The American College of Gastroenterology recommends a 4-hour scintigraphy protocol. Semaglutide should be held 48 hours prior to testing to avoid confounding results.

Small intestinal bacterial overgrowth (SIBO): Excessive gas production, bloating, and diarrhea may indicate that delayed transit has allowed proximal small bowel bacterial colonization. Glucose hydrogen breath testing can differentiate SIBO from isolated gastric fermentation.

Helicobacter pylori infection: H. pylori produces urease that generates ammonia and CO₂, but it also modulates gastric pH in ways that can promote sulfur-reducing bacterial growth. Consider testing if burps persist despite dietary changes.

Evidence-Based Management Strategies

Dietary Timing

Eating the largest meal earlier in the day, when gastric motility is naturally higher due to circadian patterns of migrating motor complex (MMC) activity, reduces evening food stagnation. The MMC is most active during fasting states and in morning hours, so consuming sulfur-rich proteins at breakfast rather than dinner exploits this window.

Meal Size Reduction

Smaller, more frequent meals reduce the total substrate load available for bacterial fermentation at any given time. The FDA prescribing information for Wegovy specifically recommends eating smaller meals to reduce gastrointestinal side effects.

Bismuth Subsalicylate

Bismuth binds H₂S in the gut lumen, forming bismuth sulfide (a black, insoluble compound). This chemical scavenging reduces sulfur gas availability by over 95% in controlled conditions. A standard dose of 262 mg taken with sulfur-rich meals can significantly reduce sulfur burps. Note: stools will turn black, which is expected and harmless.

Simethicone

While simethicone reduces surface tension of gas bubbles (aiding their coalescence and passage), it does not chemically neutralize H₂S. It may reduce the volume of eructation but will not eliminate the sulfur character of the gas.

Probiotic Considerations

Certain Lactobacillus strains compete with sulfate-reducing bacteria for substrate access. Early evidence suggests that probiotic supplementation may modestly reduce H₂S production in the upper GI tract, though no randomized trials have evaluated this specifically in GLP-1 agonist users.

When Sulfur Burps Resolve

For the majority of patients on Wegovy, sulfur burps diminish substantially once the maintenance dose is reached and held for 8-12 weeks. The STEP 5 extension trial followed participants for 104 weeks and confirmed that gastrointestinal adverse events were concentrated in the first 20 weeks, with most patients reporting stable tolerance thereafter. Partial restoration of gastric emptying through receptor adaptation, combined with learned dietary adjustments, accounts for this improvement pattern.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
3. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091. doi:10.1038/s41591-022-02026-4
4. Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619. doi:10.1111/dom.13120
5. Halawi H, Khemani D, Eckert D, et al. Effects of liraglutide on weight, satiation, and gastric functions in obesity. Gastroenterology. 2017;153(6):1579-1589. doi:10.1053/j.gastro.2017.09.055
6. Camilleri M, Chedid V, Ford AC, et al. Gastroparesis. Nat Rev Dis Primers. 2018;4(1):41. doi:10.1038/s41572-018-0038-z
7. Suarez FL, Furne J, Springfield J, Levitt MD. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology. 1998;114(5):923-929. doi:10.1016/S0016-5085(98)70311-7
8. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. FDA. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
9. Carbonero F, Benefiel AC, Alizadeh-Ghamsari AH, Gaskins HR. Microbial pathways in colonic sulfur metabolism and links with health and disease. Front Physiol. 2012;3:448. doi:10.3389/fphys.2012.00448
10. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders. Am J Gastroenterol. 2017;112(5):775-784. doi:10.1038/ajg.2017.46